This analysis quantifies MSC engraftment in glioma through MRI and BLI, suggesting noninvasive monitoring techniques.
Motivation: The engraftment status of MSCs in glioma after transplantation via different administration routes remains unclear due to the lack of quantitative analysis. Goal(s): This study aimed to quantify the engraftment of MSCs in glioma after administration via different routes using noninvasive dual-modality MRI and BLI. Approach: FTH and FLUC reporter genes-overexpressed MSCs (FTH-FLUC-MSCs) was constructed. MRI and BLI were performed to monitor FTH-FLUC-MSCs in vivo. Results: Based on quantifying by the optical signal intensity of BLI, peritumoral injection delivered a remarkable proportion of FTH-FLUC-MSCs arrived in the glioma, and a higher quantity of peritumorally injected FTH-FLUC-MSCs retained within the tumor site. Impact: FTH and FLUC reporter genes-based MRI and BLI are practical tools for noninvasively monitoring the engraftment of MSCs in vivo. Peritumoral delivery of FTH-FLUC-MSCs offers robust engraftment and could be used as the optimal delivery route for treating malignant glioma.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: